(PharmaNewsWire.Com, September 29, 2017 ) Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a person's immune system (the body's natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica (Devic's Syndrome)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 1, 5 and 7 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively.
Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
List of Tables Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Neuromyelitis Optica (Devic's Syndrome)-Pipeline by 2-BBB Medicines BV, H2 2017 Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Alexion Pharmaceuticals Inc, H2 2017 Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Apellis Pharmaceuticals Inc, H2 2017 Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Arrien Pharmaceuticals LLC, H2 2017 Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Biogen Inc, H2 2017 Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Bionure Farma SL, H2 2017 Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017 Neuromyelitis Optica (Devic's Syndrome)-Pipeline by HanAll Biopharma Co Ltd, H2 2017 Neuromyelitis Optica (Devic's Syndrome)-Pipeline by LFB SA, H2 2017 Neuromyelitis Optica (Devic's Syndrome)-Pipeline by MedImmune LLC, H2 2017 Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Opexa Therapeutics Inc, H2 2017 Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Shire Plc, H2 2017 Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Vicore Pharma AB, H2 2017 Neuromyelitis Optica (Devic's Syndrome)-Dormant Projects, H2 2017
List of Figures Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Number of Products by Top 10 Targets, H2 2017 Number of Products by Stage and Top 10 Targets, H2 2017 Number of Products by Top 10 Mechanism of Actions, H2 2017 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
